David Berry is the Founder and CEO of Valo and since 2005, has served as General Partner at Flagship Pioneering, having founded over 25 companies including Indigo Agriculture, Seres Therapeutics (NASDAQ: MCRB), Eleven Biotherapeutics (NASDAQ: EBIO), T2 Biosystems (NASDAQ: TTOO), Evelo Biosciences (NASDAQ: EVLO), Axcella Health (NASDAQ: AXLA), and Joule Unlimited. David played an instrumental role in the conception and implementation of Flagship Labs, which is the foundation of all of its companies.
David has been broadly recognized as a world-leading innovator: elected as a Young Global Leader by the World Economic Forum, named as Innovator of the Year by Technology Review from amongst its Annual TR35 list, and selected as one of 12 Innovators Reshaping Reality by the U.S. State Department, alongside pioneers such as Tim Berners-Lee. He holds over 200 patents and patent applications. David and his companies have been awarded with over 150 additional awards and honors.
David currently serves on the United Nations Sustainable Development Solutions Network (UN SDSN), where he was a Founding Leadership Council Member. David received his MD from Harvard Medical School and his PhD from MIT in Biological Engineering.
David has been broadly recognized as a world-leading innovator: elected as a Young Global Leader by the World Economic Forum, named as Innovator of the Year by Technology Review from amongst its Annual TR35 list, and selected as one of 12 Innovators Reshaping Reality by the U.S. State Department, alongside pioneers such as Tim Berners-Lee. He holds over 200 patents and patent applications. David and his companies have been awarded with over 150 additional awards and honors.
David currently serves on the United Nations Sustainable Development Solutions Network (UN SDSN), where he was a Founding Leadership Council Member. David received his MD from Harvard Medical School and his PhD from MIT in Biological Engineering.
Speaking In
10:00 AM - 10:45 AM (EST)
Monday, February 6
Strategies for Raising Venture Capital or Securing Additional Financing: Tips for Biotech Executives
With the volatility of public markets in 2022, many companies have considered additional raises…
South Broadway Ballroom